Short Interest in IPSEN (OTCMKTS:IPSEY) Expands By 2,000.0%

Key Points

• IPSEN (OTCMKTS:IPSEY) experienced a significant increase in short interest, rising by 2,000.0% from 200 to 4,200 shares between August 15th and August 31st.
• The current short-interest ratio for IPSEN is 1.6 days, based on an average daily trading volume of 2,600 shares.
• As of Thursday, IPSEN's stock price remained flat at $34.85, with a 1-year range of $25.11 to $34.96.

IPSEN (OTCMKTS:IPSEY - ) was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 4,200 shares, an increase of 2,000.0% from the August 15th total of 200 shares. Based on an average daily volume of 2,600 shares, the short-interest ratio is presently 1.6 days. Approximately 0.0% of the company's stock are short sold. Approximately 0.0% of the company's stock are short sold. Based on an average daily volume of 2,600 shares, the short-interest ratio is presently 1.6 days.

IPSEN Stock Performance

Shares of IPSEY stock remained flat at $34.85 on Thursday. 165 shares of the company traded hands, compared to its average volume of 780. IPSEN has a 1-year low of $25.11 and a 1-year high of $34.96. The firm's fifty day moving average price is $32.27 and its two-hundred day moving average price is $30.11.

IPSEN Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.